180 Life Sciences Corp. (ATNF)

US — Healthcare Sector
Peers: ZURA  PHIO  SONN  CDIO  CYTO  IMMX  ENVB  PALI  CNSP  EFTR  NAVB  ZVSA  APGN 

Automate Your Wheel Strategy on ATNF

With Tiblio's Option Bot, you can configure your own wheel strategy including ATNF - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ATNF
  • Rev/Share 0.0
  • Book/Share 2.1771
  • PB 0.4708
  • Debt/Equity 0.0193
  • CurrentRatio 1.0221
  • ROIC -0.8086

 

  • MktCap 5837873.0
  • FreeCF/Share -0.3675
  • PFCF -4.4877
  • PE -0.4858
  • Debt/Assets 0.0127
  • DivYield 0
  • ROE -1.4734

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction
ATNF
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral

PALO ALTO, CA / ACCESS Newswire / May 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), an innovative media and entertainment company focused on the global iGaming sector, with certain legacy biotechnology intellectual property assets, today announced that the United States Patent and Trademark Office ("USPTO") has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction ("POCD").

Read More
image for news 180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction
180 Life Sciences Corp. Announces Share Repurchase
ATNF
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral

PALO ALTO, CALIFORNIA / ACCESS Newswire / April 30, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences," the "Company," "we," or "us") today announced that it has entered into a Settlement and Mutual Release Agreement (the "Agreement") with Elray Resources, Inc. ("Elray") and Luxor Capital, LLC ("Luxor"). The Agreement strengthens and simplifies the Company's capital structure through a significant repurchase of shares.

Read More
image for news 180 Life Sciences Corp. Announces Share Repurchase

About 180 Life Sciences Corp. (ATNF)

  • IPO Date 2017-06-27
  • Website https://180lifesciences.com
  • Industry Biotechnology
  • CEO Mr. Lloyd Blair Jordan L.L.B., M.B.A.
  • Employees 4

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.